Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

BACKGROUND: Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4(+) T-cells. The phase 2b trial AI438011 investigated the safety, efficacy, and dose–response of fostemsavir vs ritonavir-boosted atazanavir (ATV/r) in treatment-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lataillade, Max, Zhou, Nannan, Joshi, Samit R., Lee, Sangil, Stock, David A., Hanna, George J., Krystal, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815643/
https://www.ncbi.nlm.nih.gov/pubmed/29206721
http://dx.doi.org/10.1097/QAI.0000000000001602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815643/
https://www.ncbi.nlm.nih.gov/pubmed/29206721
http://dx.doi.org/10.1097/QAI.0000000000001602

Ejemplares similares